BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 24714346)

  • 1. MicroRNA theragnostics for the clinical management of multiple myeloma.
    Ahmad N; Haider S; Jagannathan S; Anaissie E; Driscoll JJ
    Leukemia; 2014 Apr; 28(4):732-8. PubMed ID: 24714346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of circulating miRNAs in multiple myeloma.
    Zhang J; Xiao X; Liu J
    Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of miRNAs as biomarkers for multiple myeloma.
    Rocci A; Hofmeister CC; Pichiorri F
    Expert Rev Mol Diagn; 2014 Nov; 14(8):947-59. PubMed ID: 25098410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs in the pathobiology of multiple myeloma.
    Lionetti M; Agnelli L; Lombardi L; Tassone P; Neri A
    Curr Cancer Drug Targets; 2012 Sep; 12(7):823-37. PubMed ID: 22671930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA and cancer; computational and experimental approaches.
    Tutar Y
    Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.
    Soliman AM; Lin TS; Mahakkanukrauh P; Das S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma.
    Calvo KR; Landgren O; Roccaro AM; Ghobrial IM
    Semin Hematol; 2011 Jan; 48(1):39-45. PubMed ID: 21232657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of miRNAs in multiple myeloma therapy.
    Caracciolo D; Montesano M; Altomare E; Scionti F; Di Martino MT; Tagliaferri P; Tassone P
    Expert Rev Hematol; 2018 Oct; 11(10):793-803. PubMed ID: 30148649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promises and challenges of MicroRNA-based treatment of multiple myeloma.
    Tagliaferri P; Rossi M; Di Martino MT; Amodio N; Leone E; Gulla A; Neri A; Tassone P
    Curr Cancer Drug Targets; 2012 Sep; 12(7):838-46. PubMed ID: 22671926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance.
    Puła A; Robak P; Robak T
    Curr Med Chem; 2021 Oct; 28(33):6753-6772. PubMed ID: 33949926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Peripheral Blood miRNA-720 and miRNA-1246 Can Be Used as a Predictor for Outcome in Multiple Myeloma Patients.
    Ren Y; Li X; Wang W; He W; Wang J; Wang Y
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):415-423. PubMed ID: 28601493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA: important player in the pathobiology of multiple myeloma.
    Bi C; Chng WJ
    Biomed Res Int; 2014; 2014():521586. PubMed ID: 24991558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.
    Tavakoli Pirzaman A; Ebrahimi P; Hasanpour AH; Shakeri M; Babajani B; Pourali Ganji Z; Babaei H; Rahmati A; Hosseinzadeh R; Doostmohamadian S; Kazemi S
    Technol Cancer Res Treat; 2023; 22():15330338231202391. PubMed ID: 37728167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma.
    Yin Y; Yang W; Zhang L; Liu K; Luo Z
    Hematology; 2021 Dec; 26(1):160-169. PubMed ID: 33528317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
    Rossi M; Amodio N; Di Martino MT; Caracciolo D; Tagliaferri P; Tassone P
    Curr Drug Targets; 2013 Sep; 14(10):1144-9. PubMed ID: 23834146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.
    Mandilaras V; Vernon M; Meryet-Figuière M; Karakasis K; Lambert B; Poulain L; Oza A; Denoyelle C; Lheureux S
    Expert Opin Biol Ther; 2017 Aug; 17(8):927-943. PubMed ID: 28641048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs in urine as diagnostic biomarkers for multiple myeloma.
    Li J; Wang C; Meng Q; Hu Z; Hu M; Zhang M
    Int J Lab Hematol; 2021 Apr; 43(2):227-234. PubMed ID: 33068078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA deregulation in multiple myeloma.
    Bi CL; Chng WJ
    Chin Med J (Engl); 2011 Oct; 124(19):3164-9. PubMed ID: 22040573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma.
    Elkady MA; Yehia AM; Elsakka EGE; Abulsoud AI; Abdelmaksoud NM; Elshafei A; Elkhawaga SY; Ismail A; Mokhtar MM; El-Mahdy HA; Hegazy M; Elballal MS; Mohammed OA; El-Husseiny HM; Midan HM; El-Dakroury WA; Zewail MB; Abdel Mageed SS; Doghish AS
    Pathol Res Pract; 2023 Aug; 248():154704. PubMed ID: 37499518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.